indications for glp 1 agonist GI Adverse Effects of Glucagon-Like Peptide-1 Receptor Agonists GLP-1 receptor agonists and next-generation

Differences in cancer outcome definitions across trials were addressed by grouping clinically equivalent endpoints (e.g., hepatocellular carcinoma and primary liver cancer) and accounting for heterogeneity through random-effects modeling, sensitivity analyses, and GRADE downgrading for indirectness where appropriate

First-line therapies include weight loss interventions and the carbonic anhydrase inhibitors such as acetazolamide, which reduce CSF production

This creates a clear target zone for the needle and reduces the chance of intramuscular injection

10.1111/liv.70407 107 PieraliceS.AmendolaraR.BernaV.ManganaroG.ZurruA.D'OnofrioL.et al (2025)

Medication-specific pharmacokinetics play a crucial role